The secretory leukocyte protease inhibitor (SLPI) is a low-molecular-weight inhibitor of proteases, such as elastase and cathepsin G which are released from leukocytes during phagocytosis. The purpose of this study was to determine whether or not SLPI is able to inhibit IgE-mediated histamine release. Nasal mucosa from 11 test subjects without atopic disposition was used for this in vitro study. We found that SLPI inhibited histamine release in a dose-dependent way but was without influence on the spontaneous release.

**Key words:** SLPI, IgE, chymase, histamine, nasal mucosa

---

**Introduction**

Secretory leukocyte protease inhibitor (SLPI) is a non-glycosylated, acid-stable, neutral serine antiprotease first described by Haendle et al. in 1965. Isolation of native inhibitor (SLPI) from parotid juice allowed the determination of its amino acid sequence. SLPI is an important regulator of proteases such as granulocyte elastase and cathepsin G. It prevents these enzymes from inhibiting the mucociliary activity in the airways during purulent infection. It is found in great amounts in nasal secretion and is thought to be the major inhibitor of granulocyte elastase in these secretions, while α1-PI plays a minor role.

Mast cells initiate hypersensitive reactions by binding IgE to high-affinity receptors within the cell membrane in response to allergen challenge. This response causes a rapid release of several mediators, such as histamine and proteases. SLPI has been found to inhibit one of these enzymes, namely chymase. It has been found to be the fastest reacting chymase inhibitor compared with plasma inhibitors such as α1-PI and α1-antichymotrypsin. Chymase is thought to play an important role in IgE-mediated histamine release by causing mast cell degranulation. Inhibitors of chymase have been shown to inhibit IgE-mediated histamine release from isolated mast cells, probably after incorporation into mast cell granules. This implies that chymase may play a role in the stimulation of the IgE-mediated activation/secretion response. It has also been demonstrated that SLPI increases in nasal secretion when patients with atopic disposition are exposed to allergen and histamine. Neutral serine proteases such as granulocyte elastase, cathepsin G and mast cell chymase are potent secretagogues for airway gland serous cells. Histamine also degranulates serous cells, but is not such a potent secretagogue as these proteases.

The purpose of this study is to report the effect of SLPI on IgE-mediated histamine release from nasal mucosa in vitro. Another objective was to examine whether IgE-stimulation of nasal mucosa caused an increase in SLPI secretion.

**Materials and Methods**

Nasal mucosa was obtained from 11 patients undergoing conchotomy of the inferior turbinate due to nasal congestion. They were otherwise healthy patients with no known atopic predisposition. After surgery the mucosa was immediately transported to the laboratory in a sterile test tube. The mucosa from each patient was then separated from the osseous part and divided into five equally sized pieces with a scalpel. Each piece was weighed and put into a sterile test tube containing Earle's M-199 salt, (Gibco BRL, Life Technology, Täby, Sweden). To stimulate antigen cross-linking of membrane bound IgE and histamine release we used anti-IgE (DAKO, Glostrup, Denmark). RbSLPI was obtained from Synergen Inc, Boulder, CO, USA.

---

**IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release**

U. Westin, E. Lundberg and K. Ohlsson

Department of Otolaryngology and Head and Neck Surgery, and Department of Surgical Pathophysiology, University Hospital of Malmö, University of Lund, SE-205 02 Malmö, Sweden

*Corresponding Author*  
Fax: (+46) 40 336240
Assay of inhibition of histamine release

The tissue samples from each patient were pre-incubated in 2 ml of the medium for 15 min at 37°C. After preincubation a final concentration of 0, 7.5, 150 μM rhSLPI were added to three different test tubes and incubated for 15 min at 37°C. Then 15 μl anti-IgE, 15 g/l, were added to these three test tubes. Inhibition of spontaneous histamine release was measured by incubating one tissue sample with the final concentration of 150 μM rhSLPI without any anti-IgE stimulation. One test tube tissue was incubated with medium only. Incubation continued at 37°C. Samples of 200 μl were taken from each of the five test tube supernatants before (0 min), 15 min after adding rhSLPI and then the following 30, 45, 75 and 135 min.

Histamine release was measured with a commercial radioimmunoassay (RIA)-kit (Immunotech, KEMILA, Sollentuna, Sweden). The RIA-kit was able to detect non-methylated histamine. Briefly, the RIA was performed as follows: step 1, acetylation of standard solution or sample; step 2, 50 μl acetylated standard or sample and 500 μl tracer was added into antibody coated tubes and were then incubated for 18 h at 2–6°C; step 3, the coated tubes were aspirated and the total counts per minutes and bound counts per minutes were registered. Histamine release was expressed as the percentage increase or decrease relative to the sample taken before anti-IgE stimulation and after incubation with rhSLPI.

Assay of SLPI

Tissue samples from six subjects were treated as previously described. They were preincubated in 2 ml Earle’s M-199 salt, for 15 min at 37°C. A medium sample of 200 μl was removed from each test tube. One tissue sample was incubated in medium only while the other was stimulated with anti-IgE. Then 200 μl medium were collected from each test tube at 30, 45, 75 and 135 min after anti-IgE stimulation. SLPI was measured with non-competitive ELISA, as described earlier by Bergenfeldt and Ohlsson. Monoclonal mouse antibodies against SLPI (produced at our laboratory) were made to adhere to wells of microtitre plates.

Diluted samples and standard were then added. An anti-SLPI sheep IgG antiseraum (produced at our laboratory) was then added. Finally, a rabbit anti-sheep IgG antibody, conjugated with alkaline phosphatase (Dukopatt AS, Copenhagen, Denmark), was added.

Alkaline phosphatase cleaved the substrate (4-para-nitro-phenyl-phosphate). The substrate was quantified at 405 nm in an automatic Titertec multiscan photometer. To verify the effect of anti-IgE we measured the histamine release as described above. SLPI was expressed as the percentage increase compared with the sample taken before stimulation with anti-IgE.

Statistics

Regression coefficients were calculated for each histamine release curve from each one of the experiments. The hypothesis, i.e. the differences in regression coefficient were tested with a non-parametric Wilcoxon’s paired rank sum test.

The Mann–Whitney U-test was calculated on the results at 30, 45, 75 and 135 min in order to see if there was a significant increase in SLPI due to IgE stimulation.

Results

When nasal mucosa from 11 subjects were preincubated with SLPI, IgE-mediated histamine release was inhibited in a dose-dependent manner. There was significant inhibition (P = 0.028 and P = 0.015) of histamine release at SLPI concentrations of 7.5 μM and 150 μM. Inhibition was observed after 30 min incubation (Fig. 1). RhSLPI inhibited IgE-mediated histamine release to the level of spontaneous histamine release (Fig. 2), but did not affect histamine release in the absence of IgE stimulation (Fig. 3).

Pronounced IgE-mediated histamine release was observed in the absence of added rhSLPI (P = 0.0093) compared with spontaneous histamine release (Fig. 4).

The effect of IgE on nasal mucosal secretion of SLPI was also studied (six subjects). No significant increase in SLPI was observed when nasal mucosa was subjected to IgE stimulation in vitro.
Discussion

Recent studies indicate that SLPI probably plays a role as a regulator in IgE-mediated reactions, perhaps by inhibiting chymase activity.\(^\text{12,13}\) Chymase is a serine protease which resides in mast cell granules.\(^\text{16,26,27}\) Mast cell degranulation is most likely caused by chymase, thus inducing histamine release.\(^\text{15,17–19}\) We have shown that SLPI inhibits IgE-mediated histamine release in a dose-dependent manner in explanted human nasal mucosa (Fig. 1). SLPI inhibits histamine release to the level of spontaneous release (Fig. 2). These results support the suggestion that SLPI may be an important participant in allergic reactions. The findings of Dietze et al.\(^\text{12}\) suggest that preincubating tonsilar mast cells with r-MPI (SLPI) for 30 min had no effect, while incubation for 120 min restricted histamine release to the level of spontaneous release. Their study indicated that the inhibitor may not have an impact on immediate hypersensitive reactions, but is of greater importance to prolonged allergen exposure. By incubating human nasal mucosa with SLPI, we found pronounced inhibition of histamine release after 30 min, supporting the importance of SLPI as a regulator in immediate hypersensitive reactions. Whether or not SLPI forms complexes with chymase intra- or extracellularly is not known. Antibodies of chymase are incorporated into mast cell granules and inhibit histamine release, as shown by Kido et al.\(^\text{18}\) However, mast cells granules contain SLPI,\(^\text{28}\) which may indicate that the inhibitor is able to penetrate the cell membrane and act as a regulator inside the cell. It has been shown that SLPI increases in nasal secretion in allergic subjects when they are exposed to allergens.\(^\text{20}\) Serine proteases such as elastase, cathepsin G and chymase are potent secretagogues for airway gland serous cells.\(^\text{21–24}\) We proposed that chymase may also stimulate the secretion of SLPI. By incubating nasal mucosa with anti-IgE, mast cell chymase is activated and may be able to stimulate the serous cells of nasal mucosa. No significant increase in SLPI secretion could be seen, which may suggest that a nervous component is required to increase secretion in response to this kind of stimulation. In conclusion, our results obtained from experiments with intact human nasal mucosa, support the theories that SLPI plays a role in type 1 reactions by inhibiting histamine release, and that IgE does not affect SLPI secretion in nasal mucosa \textit{ex vivo}.

SLPI inhibits IgE-mediated histamine release

![FIG. 2. IgE-mediated histamine release in nasal mucosa at various concentration, 7.5 μM (–○–) and 150 μM (–▲–) of SLPI compared with spontaneously released histamine (–□–). SLPI had no influence on spontaneous histamine release.](image)

![FIG. 3. Spontaneously released histamine in nasal mucosa incubated with SLPI, 150 μM, (–□–) compared with spontaneously released histamine in the absence of SLPI (–■–). No significant inhibition of histamine release was seen in the absence of IgE-stimulation.](image)

![FIG. 4. Anti-IgE induced histamine release in nasal mucosa (–■–) compared with spontaneous release (–□–). This figure demonstrates the effect of IgE on histamine release in nasal mucosa.](image)
References

1. Haendle H, Fritz H, Trautschold I, Werle E. Über einen hormonabhängigen Inhibitor für proteolytische Enzyme in menschlichen accessorischen Geschlechtsrauen und im Sperma. Hopp- Seyler’s Physiol Chem 1965; 345: 185–188.

2. Thomson BC, Ohlsson K. Isolation properties and complete amin acid sequence of human secretory protease inhibitor, a potent inhibitor of leucocyte elastase. Proc Natl Acad Sci USA 1986; 83: 6692–6696.

3. Hochstrasser K, Reichert R, Schwartz S, Werle E. Isolierung und Charakterisierung eines Proteasen Inhibitors aus menschlichen bronchial Sekret. Hopp- Seyler’s Z Physiol Chem 1972; 353: 221.

4. Ohlsson K, Tegnér H. Granulocyte collagenase, elastase and plasma protease inhibitor in purulent sputum. Eur Clin Invest 1975; 5: 221–227.

5. Ohlsson K, Tegnér H. Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor. Scand J Clin Lab Invest 1976; 36: 437–445.

6. Tegnёр H, Ohlsson K, Toremalm NG, Mecklenburg CV. Effects of human leucocyte enzymes on tracheal mucosa and its mucociliary activity. Rhinology 1979; 17: 199–206.

7. Seemuller U, Arnold M, Fritz H et al. The acidstable proteasine inhibitor of human mucus secretions (HMSI, antileucoproteasine). FEBS Lett 1986; 199: 43–48.

8. Frykmark U, Jannert M, Ohlsson K, Whil JA, Tegnér H. Secretory leucocyte protease inhibitor in normal, allergic and virus induced nasal secretions. Rhinology 1989; 27: 97–103.

9. Westin U, Frykmark U, Polling Å, Ohlsson K. Localisation of secretory leucocyte protease inhibitor mRNA in nasal mucosa. Acta Otolaryngol 1994; 114: 199–202.

10. Igarashi Y, Kurosawa O, Ishikawa Y, Miyachi H et al. Isolerung und Charakteriserung eines Proteasen Inhibitors aus menchlichen bronkial Sekret. J Immunol 1984; 133: 437–445.

11. Wasserman SL. Mediators of immediate hypersensitivity. J Allergy Clin Immunol 1985; 72: 101–113.

12. Dietze SC, Sommerhoff GP, Fritz H. Inhibition of histamine release from human mast cells ex vivo by natural and synthetic chymase inhibitors. Biol Chem Hoppe-Seyler 1990; 371: 75–79.

13. Fink E, Nettelbeck R, Fritz H. Inhibition of mast cell chymase by eglin c and antileucoproteasine (HMSI). Biol Chem Hoppe-Seyler 1990; 371: 75–79.

14. Walter M, Piotnik M, Schechter NM. Inhibition of human mast cell chymase by secretory leucocyte protease inhibitor: enhancement of the interaction by heparin. Arch Biochem Biophys 1996; 327: 81–88.

15. Schick B, Auster KE, Schwartz LB. Activation of rat serosal mast cells by chymase, an endogenous secretory granule protease. J Immunol 1984; 133: 2571–2577.

16. Okuno-Kaneda S, Saito T, Kasawaki Y, Ichikawa A, Tomita K. Properties of proteases in mast cell granules. Biochem Pharmacol 1980; 29: 1715–1722.

17. Halstch T, Ernise M, Heidmann H. The role of chymase in ionophore-induced histamine release from human pulmonary mast cells. Advances in experimental medicine and biology. Plenum Press 1988; 240: 135–136.

18. Kido H, Fukusen N, Katuma N. Antibodies and inhibitors of chymase are incorporated into mast cell granules and inhibit histamine release. Biol Chem Hoppe-Seyler 1988; 369: 95–100.

19. Kido H, Fukusen N, Katuma N. Antibody and inhibitor of chymase inhibit histamine release in immunoglobulin E-sensitized mast cells. Biochem Int 1985; 10: 865–871.

20. H. Lee Ch, Ishiguchi Y, Hoshijima R, Kalsch B, Hohbach H. White MV, Kaliner MA. Distribution of secretory leucocyte protease inhibitor in human nasal airway. Am Rev Respir Dis 1989; 147: 710–716.

21. Sommerhoff CP, Caughey GH, Pinkheiner WE, Lazaru SG, Basbaum CB, Nadel JA. Mast cell chymase a potent secretagogue for airway gland serous cells. J Immunol 1989; 142: 2450–2456.

22. Sommerhoff CP, Fang KG, Nadel JA, Caughey H. Classical second messenger are not involved in proteinase-induced degranulation of the airway gland cells. Am J Physiol 1996; 271: 796–803.

23. Sommerhoff CP, Nadel JP, Basbaum CB, Caughey H. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990; 85: 682–689.

24. Bergendiehl M, Ohlsson K. Protease-antiprotease levels and whole blood chemiluminescence in acute peritonitis. Gastroenter Japon 1993; 28: 687–698.

25. Mathews JNS, Altman DG, Cambell MJ, Reyon P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230–235.

26. Igarashi Y, Schwartz LB. Human mast cell heterogeneity. Allergy Proc 1994; 15: 303–308.

27. Igarashi Y, Nadel JP, Basbaum CB, Caughey H. Detection of MCT and MCTC types of human mast cells by immunohistochomistry using new monoclonal anti-trypsin and anti-chymase antibodies. J Histochem Cytochem 1989; 37: 1509–1515.

28. Westin U, Polling Å, Ohlsson K. Human mast cells contain SLPI (secretory leukocyte proteinase inhibitor): demonstrated by immunohistochemistry and in situ hybridisation. Submitted.

ACKNOWLEDGEMENTS. This study was supported by grants from: The Swedish Medical Research Council (910), the Foundations of Alfred Osterlund and Johan and Greta Koch, the Medical Research Foundations of the University Hospital Malmö and the Medical Faculty, Lund University. Statistical guidance by medical statistician Jan-Åke Nilsson, University Hospital Malmö.

Received 19 January 1998; accepted in revised form 16 March 1998